ADVANCING TOWARDS CLINICAL TRIALS
Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
A novel, non‑invasive anti‑inflammatory approach
Convenient inhalation of KN‑002 delivers drug directly to the site of inflammation in the lung while minimizing systemic exposure
